Literature DB >> 23066720

Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients with significant palmoplantar involvement: a prospective, randomized study.

A B Janagond1, A J Kanwar, S Handa.   

Abstract

BACKGROUND: Palmoplantar psoriasis (PP) is a chronic, inflammatory and proliferative dermatosis of the palms and/or soles with significant morbidity. It is notoriously difficult to treat and unresponsive to traditional topical agents. MATERIAL AND METHODS  This was a prospective, randomized study involving 111 patients of psoriasis with significant palmoplantar disease. Patients meeting the eligibility criteria were randomly assigned to one of the two treatment groups. Patients in Group I received methotrexate in doses of 0.4 mg/kg weekly, and patients in Group II received acitretin in doses of 0.5 mg/kg daily. Patients were evaluated by modified PPPASI (m-PPPASI) score for palm and sole involvement at baseline, at two weekly intervals for the first 4 weeks and then four weekly for next 8 weeks. Treatment protocol was continued for a period till patient achieved 75% reduction in m-PPPASI from baseline or 12 weeks whichever was earlier.
RESULTS: There was a statistically significant difference in reduction of m-PPPASI of patients on methotrexate at weeks 8 and 12. The mean m-PPPASI at week 8 was 15.38 ± 6.08 in methotrexate group and 17.23 ± 5.25 in acitretin group (P = 0.04). The mean m-PPPASI at week 12 was 10.30 ± 5.97 in methotrexate group and 12.40 ± 5.31 in acitretin group (P = 0.03). Marked improvement (m-PPPASI 75) was achieved in 12 (24%) patients in methotrexate group compared with 4 (8%) in acitretin group which was statistically significant (P = 0.029). Adverse events were generally mild and were seen in 14 patients in methotrexate group and 15 patients in acitretin group (P = 0.080).
CONCLUSION: Methotrexate is relatively inexpensive, safe and efficacious drug for the treatment of psoriasis patients with significant palmoplantar involvement. Acitretin can be used as an alternative therapy and with a good safety profile.
© 2012 The Authors. Journal of the European Academy of Dermatology and Venereology © 2012 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23066720     DOI: 10.1111/jdv.12004

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  10 in total

Review 1.  Secukinumab in the Treatment of Palmoplantar, Nail, Scalp, and Pustular Psoriasis.

Authors:  April W Armstrong; Ron Vender; Leon Kircik
Journal:  J Clin Aesthet Dermatol       Date:  2016-06-01

2.  Comparison of the Efficacy and Safety of Apremilast and Methotrexate in Patients with Palmoplantar Psoriasis: A Randomized Controlled Trial.

Authors:  Soufila Kt; Vishal Thakur; Tarun Narang; Sunil Dogra; Sanjeev Handa
Journal:  Am J Clin Dermatol       Date:  2021-03-12       Impact factor: 7.403

Review 3.  Pain Management in Painful Psoriasis and Psoriatic Arthropathy: Challenging and Intricately Intertwined Issues Involving Several Systems.

Authors:  Vijay Kodumudi; Kanishka Rajput
Journal:  Curr Pain Headache Rep       Date:  2021-04-06

4.  Safety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials.

Authors:  Jonathan West; Simon Ogston; John Foerster
Journal:  PLoS One       Date:  2016-05-11       Impact factor: 3.240

5.  Psoriasis: Epidemiology, clinical features, co-morbidities, and clinical scoring.

Authors:  Sunil Dogra; Rahul Mahajan
Journal:  Indian Dermatol Online J       Date:  2016 Nov-Dec

Review 6.  Evidence and Suggested Therapeutic Approach in Psoriasis of Difficult-to-treat Areas: Palmoplantar Psoriasis, Nail Psoriasis, Scalp Psoriasis, and Intertriginous Psoriasis.

Authors:  Nilendu Sarma
Journal:  Indian J Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.494

Review 7.  Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails.

Authors:  Joseph F Merola; Abrar Qureshi; M Elaine Husni
Journal:  Dermatol Ther       Date:  2018-03-06       Impact factor: 2.851

8.  Influences of methotrexate iontophoresis on functional lifestyle disabilities, functional capacity, and pain in patients with plantar psoriasis.

Authors:  Nermeen Mohamed Abdelhalim; Ahmed Fathy Samhan
Journal:  Turk J Phys Med Rehabil       Date:  2022-06-01

9.  Interventions for chronic palmoplantar pustulosis.

Authors:  Grace Obeid; Giao Do; Lisa Kirby; Carolyn Hughes; Emilie Sbidian; Laurence Le Cleach
Journal:  Cochrane Database Syst Rev       Date:  2020-01-20

10.  How frequently does palmoplantar psoriasis affect the palms and/or soles? A systematic review and meta-analysis.

Authors:  Zorica Sojević Timotijević; Goran Trajković; Janko Jankovic; Milijana Relić; Dragica Đorić; Danica Vukićević; Goran Relić; Dragiša Rašić; Milan Filipović; Slavenka Janković
Journal:  Postepy Dermatol Alergol       Date:  2019-11-12       Impact factor: 1.837

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.